Subscribe
istock-518782097-drazen_
Drazen_ / iStockphoto.com
28 June 2018Big Pharma

Swiss Federal Supreme Court to adopt EU SPC case law

Switzerland’s highest court held that new supplementary protection certificates (SPCs) for combination products should be governed by the relevant EU law, in a dispute over a Swiss SPC owned by Gilead Sciences.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

article
Swiss scientist convicted for GSK trade secrets theft
3 May 2022   A scientist working in Switzerland has been convicted of conspiring with his sister and others to steal trade secrets from GlaxoSmithKline for the benefit of their respective biopharmaceutical ventures.
Big Pharma
Swiss IP office issues SPC clarification
8 November 2018   The Swiss Federal Institute of Intellectual Property has issued a notice covering a change in the practice for granting supplementary protection certificates (SPCs), following a landmark decision by Switzerland’s highest court.
Big Pharma
AG opines on ‘thorny issue’ in Truvada SPC clash
25 April 2018   Advocate General Melchior Wathelet has advised the Court of Justice of the European Union on a case involving a supplementary protection certificate.


Editor's picks

A step too far? Why Stewart’s approach is dividing opinion
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025

Editor's picks

Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025

More on this story

article
Swiss scientist convicted for GSK trade secrets theft
3 May 2022   A scientist working in Switzerland has been convicted of conspiring with his sister and others to steal trade secrets from GlaxoSmithKline for the benefit of their respective biopharmaceutical ventures.
Big Pharma
Swiss IP office issues SPC clarification
8 November 2018   The Swiss Federal Institute of Intellectual Property has issued a notice covering a change in the practice for granting supplementary protection certificates (SPCs), following a landmark decision by Switzerland’s highest court.
Big Pharma
AG opines on ‘thorny issue’ in Truvada SPC clash
25 April 2018   Advocate General Melchior Wathelet has advised the Court of Justice of the European Union on a case involving a supplementary protection certificate.

More on this story

article
Swiss scientist convicted for GSK trade secrets theft
3 May 2022   A scientist working in Switzerland has been convicted of conspiring with his sister and others to steal trade secrets from GlaxoSmithKline for the benefit of their respective biopharmaceutical ventures.
Big Pharma
Swiss IP office issues SPC clarification
8 November 2018   The Swiss Federal Institute of Intellectual Property has issued a notice covering a change in the practice for granting supplementary protection certificates (SPCs), following a landmark decision by Switzerland’s highest court.
Big Pharma
AG opines on ‘thorny issue’ in Truvada SPC clash
25 April 2018   Advocate General Melchior Wathelet has advised the Court of Justice of the European Union on a case involving a supplementary protection certificate.

More features

Bankruptcy judge approves $305m sale of genetics testing company
Sanofi successfully challenges rare disease patent in Europe
Bayer appoints new head of IP
WATCH: Policy direction—where are we now?
Broad Institute wins appeal to restore CRISPR patent in Europe
BMS faces fresh lawsuit over alleged cancer drug monopoly
WATCH: Synergy in science—navigating the landscape of pharmaceutical collaborations
Boies Schiller Flexner adds three-strong litigation team